HIV-1 vaccines and adaptive trial designs

Lawrence Corey, Gary J. Nabel, Carl Dieffenbach, Peter Gilbert, Barton F. Haynes, Margaret Johnston, James Kublin, H. Clifford Lane, Giuseppe Pantaleo, Louis Picker, Anthony S. Fauci

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

Developing a vaccine against the human immunodeficiency virus (HIV) poses an exceptional challenge. There are no documented cases of immune-mediated clearance of HIV from an infected individual, and no known correlates of immune protection. Although nonhuman primate models of lentivirus infection have provided valuable data about HIV pathogenesis, such models do not predict HIV vaccine efficacy in humans. The combined lack of a predictive animal model and undefined biomarkers of immune protection against HIV necessitate that vaccines to this pathogen be tested directly in clinical trials. Adaptive clinical trial designs can accelerate vaccine development by rapidly screening out poor vaccines while extending the evaluation of efficacious ones, improving the characterization of promising vaccine candidates and the identification of correlates of immune protection.

Original languageEnglish (US)
Article number79ps13
JournalScience Translational Medicine
Volume3
Issue number79
DOIs
StatePublished - Apr 20 2011

Fingerprint

HIV-1
Vaccines
HIV
Lentivirus Infections
Primate Lentiviruses
Clinical Trials
Animal Models
Biomarkers

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Corey, L., Nabel, G. J., Dieffenbach, C., Gilbert, P., Haynes, B. F., Johnston, M., ... Fauci, A. S. (2011). HIV-1 vaccines and adaptive trial designs. Science Translational Medicine, 3(79), [79ps13]. https://doi.org/10.1126/scitranslmed.3001863

HIV-1 vaccines and adaptive trial designs. / Corey, Lawrence; Nabel, Gary J.; Dieffenbach, Carl; Gilbert, Peter; Haynes, Barton F.; Johnston, Margaret; Kublin, James; Clifford Lane, H.; Pantaleo, Giuseppe; Picker, Louis; Fauci, Anthony S.

In: Science Translational Medicine, Vol. 3, No. 79, 79ps13, 20.04.2011.

Research output: Contribution to journalArticle

Corey, L, Nabel, GJ, Dieffenbach, C, Gilbert, P, Haynes, BF, Johnston, M, Kublin, J, Clifford Lane, H, Pantaleo, G, Picker, L & Fauci, AS 2011, 'HIV-1 vaccines and adaptive trial designs', Science Translational Medicine, vol. 3, no. 79, 79ps13. https://doi.org/10.1126/scitranslmed.3001863
Corey L, Nabel GJ, Dieffenbach C, Gilbert P, Haynes BF, Johnston M et al. HIV-1 vaccines and adaptive trial designs. Science Translational Medicine. 2011 Apr 20;3(79). 79ps13. https://doi.org/10.1126/scitranslmed.3001863
Corey, Lawrence ; Nabel, Gary J. ; Dieffenbach, Carl ; Gilbert, Peter ; Haynes, Barton F. ; Johnston, Margaret ; Kublin, James ; Clifford Lane, H. ; Pantaleo, Giuseppe ; Picker, Louis ; Fauci, Anthony S. / HIV-1 vaccines and adaptive trial designs. In: Science Translational Medicine. 2011 ; Vol. 3, No. 79.
@article{7f9b213e93c94dfa95c12813d047f2c2,
title = "HIV-1 vaccines and adaptive trial designs",
abstract = "Developing a vaccine against the human immunodeficiency virus (HIV) poses an exceptional challenge. There are no documented cases of immune-mediated clearance of HIV from an infected individual, and no known correlates of immune protection. Although nonhuman primate models of lentivirus infection have provided valuable data about HIV pathogenesis, such models do not predict HIV vaccine efficacy in humans. The combined lack of a predictive animal model and undefined biomarkers of immune protection against HIV necessitate that vaccines to this pathogen be tested directly in clinical trials. Adaptive clinical trial designs can accelerate vaccine development by rapidly screening out poor vaccines while extending the evaluation of efficacious ones, improving the characterization of promising vaccine candidates and the identification of correlates of immune protection.",
author = "Lawrence Corey and Nabel, {Gary J.} and Carl Dieffenbach and Peter Gilbert and Haynes, {Barton F.} and Margaret Johnston and James Kublin and {Clifford Lane}, H. and Giuseppe Pantaleo and Louis Picker and Fauci, {Anthony S.}",
year = "2011",
month = "4",
day = "20",
doi = "10.1126/scitranslmed.3001863",
language = "English (US)",
volume = "3",
journal = "Science Translational Medicine",
issn = "1946-6234",
publisher = "American Association for the Advancement of Science",
number = "79",

}

TY - JOUR

T1 - HIV-1 vaccines and adaptive trial designs

AU - Corey, Lawrence

AU - Nabel, Gary J.

AU - Dieffenbach, Carl

AU - Gilbert, Peter

AU - Haynes, Barton F.

AU - Johnston, Margaret

AU - Kublin, James

AU - Clifford Lane, H.

AU - Pantaleo, Giuseppe

AU - Picker, Louis

AU - Fauci, Anthony S.

PY - 2011/4/20

Y1 - 2011/4/20

N2 - Developing a vaccine against the human immunodeficiency virus (HIV) poses an exceptional challenge. There are no documented cases of immune-mediated clearance of HIV from an infected individual, and no known correlates of immune protection. Although nonhuman primate models of lentivirus infection have provided valuable data about HIV pathogenesis, such models do not predict HIV vaccine efficacy in humans. The combined lack of a predictive animal model and undefined biomarkers of immune protection against HIV necessitate that vaccines to this pathogen be tested directly in clinical trials. Adaptive clinical trial designs can accelerate vaccine development by rapidly screening out poor vaccines while extending the evaluation of efficacious ones, improving the characterization of promising vaccine candidates and the identification of correlates of immune protection.

AB - Developing a vaccine against the human immunodeficiency virus (HIV) poses an exceptional challenge. There are no documented cases of immune-mediated clearance of HIV from an infected individual, and no known correlates of immune protection. Although nonhuman primate models of lentivirus infection have provided valuable data about HIV pathogenesis, such models do not predict HIV vaccine efficacy in humans. The combined lack of a predictive animal model and undefined biomarkers of immune protection against HIV necessitate that vaccines to this pathogen be tested directly in clinical trials. Adaptive clinical trial designs can accelerate vaccine development by rapidly screening out poor vaccines while extending the evaluation of efficacious ones, improving the characterization of promising vaccine candidates and the identification of correlates of immune protection.

UR - http://www.scopus.com/inward/record.url?scp=79955016281&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955016281&partnerID=8YFLogxK

U2 - 10.1126/scitranslmed.3001863

DO - 10.1126/scitranslmed.3001863

M3 - Article

VL - 3

JO - Science Translational Medicine

JF - Science Translational Medicine

SN - 1946-6234

IS - 79

M1 - 79ps13

ER -